Please use this identifier to cite or link to this item: https://hdl.handle.net/1/260
Title: Test Performance of Faecal Occult Blood Testing for the Detection of Bowel Cancer in People with Chronic Kidney Disease (DETECT) Protocol
Authors: Wong, Germaine ;Howard, K.;Chapman, J.R.;Tong, Allison ;Bourke, Michael ;Hayen, Andrew ;Macaskill, P.;Hope, Richard ;Williams, Narelle ;Kieu, Anh ;Allen, Richard ;Chadban, Steven ;Pollock, Carol ;Webster, Angela C ;Roger, Simon D ;Craig, J.C.
Issue Date: Jun-2011
Source: Volume 11, Issue 1, pp. 1-7
Journal title: BioMed Central Public Health
Abstract: Background: Cancer is a major cause of mortality and morbidity in patients with chronic kidney disease (CKD). In patients without kidney disease, screening is a major strategy for reducing the risk of cancer and improving the health outcomes for those who developed cancers by detecting treatable cancers at an early stage. Among those with CKD, the effectiveness, the efficacy and patients’ preferences for cancer screening are unknown. Methods/Design: This work describes the protocol for the DETECT study examining the effectiveness, efficiency and patient’s perspectives of colorectal cancer screening using immunochemical faecal occult blood testing (iFOBT) for people with CKD. The aims of the DETECT study are 1) to determine the test performance characteristics of iFOBT screening in individuals with CKD, 2) to estimate the incremental costs and health benefits of iFOBT screening in CKD compared to no screening and 3) to elicit patients’ perspective for colorectal cancer screening in the CKD population. Three different study designs will be used to explore the uncertainties surrounding colorectal cancer screening in CKD. A diagnostic test accuracy study of iFOBT screening will be conducted across all stages of CKD in patients ages 35-70. Using individually collected direct healthcare costs and outcomes from the diagnostic test accuracy study, cost-utility and cost-effective analyses will be performed to estimate the costs and health benefits of iFOBT screening in CKD. Qualitative in-depth interviews will be undertaken in a subset of participants from the diagnostic test accuracy study to investigate the perspectives, experiences, attitudes and beliefs about colorectal cancer screening among individuals with CKD. Discussion: The DETECT study will target the three major unknowns about early cancer detection in CKD. Findings from our study will provide accurate and definitive estimates of screening efficacy and efficiency for colorectal cancer, and will allow better service planning and budgeting for early cancer detection in this at-risk population. The DETECT study is also registered with the Australia New Zealand Clinical Trials Registry ACTRN12611000538943
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/260
DOI: 10.1186/1471-2458-11-516
Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/21714917
ISSN: 1471-2458
Publicaton type: Journal Article
Keywords: Kidney Disease
Cancer
Study or Trial: Clinical Trial
Appears in Collections:Renal Medicine

Files in This Item:
File Description SizeFormat 
10.1186_1471-2458-11-516.pdfWongG, 2011, Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol206.74 kBAdobe PDFThumbnail
View/Open
Show full item record

Page view(s)

8
checked on Jan 28, 2023

Download(s)

6
checked on Jan 28, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.